UBS’s Filana Therapeutics FLNA Stock Holding History

UBS’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-329	Closed	-$6K	–	10715
2013 Q3	$6K	Buy	+329	New	+$5.75K	﹤0.01%	9277

Other funds holding FLNA

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

MSP

Madison Street Partners Denver, Colorado $3.05M AUM 5.94% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

UBS's FLNA Position: Q3 2014 in Review

UBS sold out of Filana Therapeutics (FLNA) in Q3 2014, closing a stake of 714 shares — an estimated $29K sold.

UBS first reported a position in FLNA in Q2 2013 and held it in 3 quarters. The position peaked at $620K in Q1 2014. 73 funds tracked by Wall St. Rank hold FLNA as of Q3 2014.

UBS reported no remaining Filana Therapeutics position as of Q3 2014 after selling out during the quarter.
UBS sold 714 Filana Therapeutics shares in Q3 2014, an estimated $29K.
UBS first reported a position in Filana Therapeutics in Q2 2013 and held it in 3 quarters.
UBS's Filana Therapeutics position peaked at $620K in Q1 2014.
73 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.